ACAD 8-K SEC Filing Analysis

Latest settled — T+20d

ACAD ▼ -5.01% at T+20d

SHORT call ✓ call won +5.01% · α vs SPY +8.14% · entry $22.56 → $21.43

Next anchor: T+60d in 7w

Currently $21.09 · +6.52% from $22.56 entry (call sign-flipped)

Entry anchored
May 6, 04:17 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.83%

$22.56

settled 5w ago

T+5d

-1.68%

call +1.68% · α +3.19%

$22.18

settled 4w ago

T+20d

-5.01%

call +5.01% · α +8.14%

$21.43

settled 9d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.

Key Financial Metrics

Guidance

$1.22B-$1.28B

maintained

Actionable Insight

EPS miss of 75% vs consensus will pressure the stock near-term. Monitor analyst reactions and any cost control initiatives. The DAYBUE growth and guidance reaffirmation provide a floor, but rising SG&A is a concern.

Key Facts

Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
SG&A expense $171M, up 36% from $126M YoY, driving operating loss
DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)
Full-year 2026 guidance reaffirmed: revenue $1.22-1.28B

Financial Impact

EPS miss of 75% vs consensus ($0.02 actual vs $0.08 est); revenue miss of ~4%

epsnetIncomeoperatingIncome

Risk Factors

Continued SG&A cost inflation without corresponding revenue acceleration
Remlifanserin Phase 2 data risk (readout Aug-Oct 2026)
IRA rebate adjustments may cause further earnings volatility

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

78% bullish (27 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-209253
Document: acad-20260506.htm	0001193125-26-209253
Document: 0001193125-26-209253-index-headers.html	0001193125-26-209253
Document: 0001193125-26-209253-index.html	0001193125-26-209253
Document: 0001193125-26-209253.txt	0001193125-26-209253
8-K Data (Synthetic)	0001193125-26-209253

6 reports for ACAD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ACAD — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	Institutional Cluster BEARISH ★ 6/10	$21.18 awaiting T+20	awaiting T+20	—	$21.09 (+0.42%)
May 6, 2026 5w ago	8-K BEARISH ★ 6/10	$22.56 $21.43	▲ +5.01%	▲ +8.14%	$21.09 (+6.52%)
May 4, 2026 5w ago	Insider Cluster NEUTRAL ★ 2/10	$22.19 $21.52	▼ −3.02%	▼ −8.66%	$21.09 (−4.96%)
Mar 25, 2026 11w ago	Insider Cluster NEUTRAL ★ 4/10	$22.01 $22.11	▲ +0.45%	▼ −7.41%	$21.09 (−4.18%)
Mar 5, 2026 14w ago	8-K NEUTRAL ★ 3/10	$22.40 $22.20	▼ −0.89%	▲ +2.90%	$21.09 (−5.85%)
Feb 25, 2026 15w ago	8-K BULLISH ★ 8/10	$24.64 $21.47	▼ −12.87%	▼ −6.46%	$21.09 (−14.41%)

US Market Status

Market Closed — Opens Mon (49h 32m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access